1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global In-Vitro ADME Services Market
2.2. Global In-Vitro ADME Services Market, By Type, 2023 (US$ Million)
2.3. Global In-Vitro ADME Services Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. In-Vitro ADME Services Market: Competitive Analysis
3.1. Market Positioning of Key In-Vitro ADME Services Market Vendors
3.2. Strategies Adopted by In-Vitro ADME Services Market Vendors
3.3. Key Industry Strategies
4. In-Vitro ADME Services Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global In-Vitro ADME Services Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Solution Properties
5.3.2. Drug Absorption & Transport
5.3.3. Drug Metabolism
5.3.4. Drug – Drug Interactions


6. North America In-Vitro ADME Services Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
6.3.In-Vitro ADME Services Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)

7. UK and European Union In-Vitro ADME Services Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.In-Vitro ADME Services Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)

8. Asia Pacific In-Vitro ADME Services Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.In-Vitro ADME Services Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)

9. Latin America In-Vitro ADME Services Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
9.3.In-Vitro ADME Services Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)

10. Middle East and Africa In-Vitro ADME Services Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
10.3.In-Vitro ADME Services Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. In-Vitro ADME Services Market: By Type, 2022-2032, USD (Million)

11. Company Profile
11.1. Absorption Systems LP
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Albany Molecular Research, Inc. (AMRI)
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Aptagen, LLC
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. BIOalternatives SAS
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Sigma-Aldrich Co. LLC/ MilliporeSigma
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. BioTeSys GmbH
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Calvert Labs
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. XenoTech, LLC
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Cyprotex PLC
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Qualyst Transporter Solution, LLC
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Solvo Biotechnology
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. TNO
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. WuXiAppTec
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Centrillion Technology Holdings Ltd.
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. In Vitro ADMET Laboratories, LLC
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives
11.16. Covance, Inc.
11.16.1. Company Overview
11.16.2. Financial Performance
11.16.3. Product Portfolio
11.16.4. Strategic Initiatives
11.17. Quintiles IMS Holdings, Inc.
11.17.1. Company Overview
11.17.2. Financial Performance
11.17.3. Product Portfolio
11.17.4. Strategic Initiatives
11.18. Optivia Biotechnology Inc.
11.18.1. Company Overview
11.18.2. Financial Performance
11.18.3. Product Portfolio
11.18.4. Strategic Initiatives
11.19. PharmaronBeijing Company Ltd.
11.19.1. Company Overview
11.19.2. Financial Performance
11.19.3. Product Portfolio
11.19.4. Strategic Initiatives
11.20. Quest Pharmaceutical Services Holdings LLC
11.20.1. Company Overview
11.20.2. Financial Performance
11.20.3. Product Portfolio
11.20.4. Strategic Initiatives
11.21. Thermo Fisher Scientific Inc.
11.21.1. Company Overview
11.21.2. Financial Performance
11.21.3. Product Portfolio
11.21.4. Strategic Initiatives
11.22. Charles River Laboratories International, Inc.
11.22.1. Company Overview
11.22.2. Financial Performance
11.22.3. Product Portfolio
11.22.4. Strategic Initiatives
11.23. EurofinsCerep SA
11.23.1. Company Overview
11.23.2. Financial Performance
11.23.3. Product Portfolio
11.23.4. Strategic Initiatives
11.24. Admescope
11.24.1. Company Overview
11.24.2. Financial Performance
11.24.3. Product Portfolio
11.24.4. Strategic Initiatives
11.25. Agilux
11.25.1. Company Overview
11.25.2. Financial Performance
11.25.3. Product Portfolio
11.25.4. Strategic Initiatives
11.26. Alliance Pharma
11.26.1. Company Overview
11.26.2. Financial Performance
11.26.3. Product Portfolio
11.26.4. Strategic Initiatives
11.27. BD Biosciences
11.27.1. Company Overview
11.27.2. Financial Performance
11.27.3. Product Portfolio
11.27.4. Strategic Initiatives
11.28. Frontage Laboratories
11.28.1. Company Overview
11.28.2. Financial Performance
11.28.3. Product Portfolio
11.28.4. Strategic Initiatives
11.29. MICROCONSTANTS, INC.
11.29.1. Company Overview
11.29.2. Financial Performance
11.29.3. Product Portfolio
11.29.4. Strategic Initiatives